Lv1
60 积分 2025-03-23 加入
Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction
11小时前
待确认
Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)‐α level and the efficacy of TNF‐inhibitor therapy in psoriasis
12小时前
已完结
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence
12小时前
已完结
PHOENIX 2 Investigators. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
13小时前
求助中
Population Pharmacokinetics of Xeligekimab: An Anti‐IL‐17A Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis
1天前
已完结
Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial
3天前
已完结
Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
16天前
已完结
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
16天前
已完结
Single-cell technologies in psoriasis
19天前
已完结
IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis
25天前
已完结
皖公网安备34019202002308
